Hvilken er prisen på Bristol-Myers Squibb Company (BMY)

Prisen på Bristol-Myers Squibb Company (BMY) er $59.43

Hva er markedsverdien på Bristol-Myers Squibb Company (BMY)

Markedsverdien på Bristol-Myers Squibb Company (BMY) er $121.03B

Bristol-Myers Squibb Company (BMY) Utestående Aksjer

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

År	Utestående aksjer	Endre
2026 (TTM)	2.04B	0.00%
2025	2.04B	0.69%
2024	2.03B	-2.03%
2023	2.07B	-2.86%
2022	2.13B	-4.10%
2021	2.22B	-1.64%
2020	2.26B	32.43%
2019	1.71B	4.41%
2018	1.63B	-0.73%
2017	1.65B	-1.56%
2016	1.67B	0.24%
2015	1.67B	0.60%
2014	1.66B	0.79%
2013	1.64B	-1.56%
2012	1.67B	-1.76%
2011	1.70B	-0.76%
2010	1.71B	-13.22%
2009	1.97B	-0.15%
2008	1.98B	0.36%
2007	1.97B	0.51%
2006	1.96B	0.41%
2005	1.95B	0.51%
2004	1.94B	0.26%
2003	1.94B	-3.01%
2002	2.00B	2.95%
2001	1.94B	-1.27%
2000	1.97B	0.00%

År

Utestående aksjer

Endre

2026 (TTM)

2.04B

0.00%

2025

2.04B

0.69%

2024

2.03B

-2.03%

2023

2.07B

-2.86%

2022

2.13B

-4.10%

2021

2.22B

-1.64%

2020

2.26B

32.43%

2019

1.71B

4.41%

2018

1.63B

-0.73%

2017

1.65B

-1.56%

2016

1.67B

0.24%

2015

1.67B

0.60%

2014

1.66B

0.79%

2013

1.64B

-1.56%

2012

1.67B

-1.76%

2011

1.70B

-0.76%

2010

1.71B

-13.22%

2009

1.97B

-0.15%

2008

1.98B

0.36%

2007

1.97B

0.51%

2006

1.96B

0.41%

2005

1.95B

0.51%

2004

1.94B

0.26%

2003

1.94B

-3.01%

2002

2.00B

2.95%

2001

1.94B

-1.27%

2000

1.97B

0.00%

Selskap	Utestående aksjer	Forskjell	Land
Eli Lilly LLY.US	898.00M	-56.00%	US
AstraZeneca PLC AZN.US	3.10B	51.89%	GB
Johnson & Johnson JNJ.US	2.43B	18.99%	US
AbbVie Inc. ABBV.US	1.78B	-12.77%	US
Novartis AG NVS.US	1.91B	-6.27%	CH

Selskap

Utestående aksjer

Forskjell

Land